Stockwatch: Some Failed Drugs Never Die, They Just Find New Investors
Cytokinetics and Synairgen Are Cases In Point
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.
